Haptoglobin phenotypes, which one is better and when?

被引:0
作者
Zvi, B [1 ]
Levy, AP [1 ]
机构
[1] Rambam Med Ctr, Dept Nephrol, Haifa, Israel
关键词
haptoglobin; Hp; phenotypes; CVD; dialysis; CKD; diabetes; Hb clearance;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Haptoglobin (Hp) phenotype 2-2 presents characteristics of being an independent risk factor for cardiovascular disease (CVD) and more significant in diabetic CVD. In chronic kidney disease (CKD), due to various processes that take place simultaneously, the combined effect is different in the elderly and the young. In older patients (> 60 years), Hp 2-2 is associated with a greater risk for cardiovascular and renal morbidity and mortality. In younger (< 60 years) hemodialysis patients, infections and high hemoglobin turnover are predominant, and patients with Hp 2-2 have a longer survivorship than those with Hp 1-1. The functional differences between the Hp phenotypes are most probably due to their antioxidative property and to macrophage activation with differential release of cytokines.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
  • [31] INVOLVEMENT OF HAPTOGLOBIN PHENOTYPES AND GENOTYPES IN NON-MUSCLE INVASIVE BLADDER CANCER: A POSSIBLE PROGNOSTIC MARKER FOR RISK STRATIFICATION
    Aghaalikhani, Nazi
    Zamani, Mojtaba
    Allameh, Abdolamir
    Mashayekhi, Amir
    Shadpour, Pejman
    Mahmoodi, Marzieh
    Rashtchizadeh, Nadereh
    [J]. EXCLI JOURNAL, 2020, 19 : 351 - 359
  • [32] Antithrombotic therapy in diabetes: which, when, and for how long?
    Ajjan, Ramzi A.
    Kietsiriroje, Noppadol
    Badimon, Lina
    Vilahur, Gemma
    Gorog, Diana A.
    Angiolillo, Dominick J.
    Russell, David A.
    Rocca, Bianca
    Storey, Robert F.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (23) : 2235 - 2259
  • [33] Severe Asthma and Biological Therapy: When, Which, and for Whom
    Paola Rogliani
    Luigino Calzetta
    Maria Gabriella Matera
    Rossella Laitano
    Beatrice Ludovica Ritondo
    Nicola A. Hanania
    Mario Cazzola
    [J]. Pulmonary Therapy, 2020, 6 : 47 - 66
  • [34] Severe Asthma and Biological Therapy: When, Which, and for Whom
    Rogliani, Paola
    Calzetta, Luigino
    Matera, Maria Gabriella
    Laitano, Rossella
    Ritondo, Beatrice Ludovica
    Hanania, Nicola A.
    Cazzola, Mario
    [J]. PULMONARY THERAPY, 2020, 6 (01) : 47 - 66
  • [35] Glomerular filtration rate: when to measure and in which patients?
    Agarwal, Rajiv
    Delanaye, Pierre
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (12) : 2001 - 2007
  • [36] During the pre-dialysis stage of chronic kidney disease, which treatment is associated with better survival in dialysis?
    Caravaca, Francisco
    Alvarado, Raul
    Garcia-Pino, Guadalupe
    Martinez-Gallardo, Rocio
    Luna, Enrique
    [J]. NEFROLOGIA, 2014, 34 (04): : 469 - 476
  • [37] Evaluation of neuronal inflammation and oxidative DNA damage in different haptoglobin phenotypes of Nigerian type-2 diabetes mellitus population
    Odeyinka, O. Odewusi
    Ofejiro, B. Ogberetitinor
    Wendy, A. Ijeh
    Olalere, S. Obadire
    Olayinka, O. Olaniyan
    [J]. JOURNAL OF KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITY, 2023, 12 (03) : 50 - 62
  • [38] Age-related changes in haptoglobin phenotypes, some non-enzymatic antioxidants and electrophoretic profiles of serum proteins in rats
    Ciftci, Gulay
    Yarim, Gul Fatma
    Cenesiz, Sena
    Findik, Arzu
    [J]. TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2012, 37 (04): : 457 - 462
  • [39] When to initiate dialysis-is an early start always better?
    Liberek, Tomasz
    Warzocha, Alicja
    Galgowska, Joanna
    Taszner, Katarzyna
    Clark, William F.
    Rutkowski, Boleslaw
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (07) : 2087 - 2091
  • [40] Developing a better mouse model of Alzheimer disease with clinically relevant phenotypes in tau pathology
    SUN An-yang
    [J]. 中国药理学与毒理学杂志, 2018, 32 (09) : 687 - 688